On May 4, 2021, Chiasma, Inc. (NASDAQ: CHMA), a Newton, Massachusetts-based biopharmaceutical company, signed a definitive merger agreement to be acquired by Amryt Pharma plc (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, in an all-stock deal.
Duff & Phelps, A Kroll Business, served as a financial advisor to the board of directors of Chiasma and provided an independent fairness opinion in connection with the transaction.
About Chiasma, Inc. (NASDAQ: CHMA)
Chiasma is a commercial stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. Goodwin Procter LLP served as legal counsel to Chiasma.
About Amryt Pharma plc (NASDAQ: AMYT, AIM: AMYT)
Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets. Gibson, Dunn & Crutcher LLP served as legal counsel to Amryt.
Fairness and Solvency Opinions
Independent opinions for boards of directors and special committees.
SPAC Advisory Services
Focused expertise for SPAC transactions.
Private Capital Markets – Debt Advisory
Senior, subordinated and mezzanine debt and venture/private equity for a wide range of transactions.
Middle-market M&A advisory differentiated by industry expertise and superior deal execution.
Transaction Advisory Services
Seamless analytical advisory through the deal continuum, from transaction origination to closing.
European Chemicals Update – Q4 2021
Insider Threat Indicators and Detection: When Employees Turn Ransomware Accomplices
The THIP Model: Embedding Emotional Intelligence in Third-Party Risk Management
Valuation Insights – Fourth Quarter 2021
Kroll Unifies Brand to Reflect Strategic Growth and Vision
Kroll Appoints David Lewis, Former Executive Secretary of the FATF, as a Managing Director to Lead its AML Advisory Practice
Who’s Who Legal Recognizes Six Kroll Professionals in the Fields of Financial Restructuring and Insolvency Worldwide
Prime Clerk, A Kroll Business, Welcomes Former Kirkland & Ellis Partner Brad Weiland to Its Team